Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$428.59 USD
-1.34 (-0.31%)
Updated May 14, 2024 04:00 PM ET
After-Market: $431.99 +3.40 (0.79%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 1 - 20 ( 324 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Povetacicept Boosts Kidney Franchise While Opening Door to Immunoinflammatory Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
VX-548 Key Metric Remains Analgesia at 48 hours For Prescriber Uptake; Reiterate Buy; PT Up to $457
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
DPN Phase 2 Data Validates Targeting of Peripheral NaV Channels
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Casgevy Approval Sparks Increased Interest in Genome Editing Launch Dynamics; Reiterating Buy and Increasing PT to $397
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for VRTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Expectations for Phase 2 DPN Trial; Reiterate Buy and PT Up to $390
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
AdCom Panelists Support Vertexs Safety Analysis For Exa-Cel
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A